Thereafter, we exposed multiple AML or acute lymphoid leukemia (ALL) cell lines to the newly synthesized inhibitor EC-134, as well as to the CBX7 inhibitors MS452 and BDA-41 (see Table 1 for information about the inhibitors). Here, CBX7 is linked to acute myeloid leukemia.